Background Hypertrophic cardiaomyopathy(HCM) is characterized by asymmetric myocardial hypertrophy, mainly involving ventricular septum. Current treatment methods for HCM include drugs, interventional and surgical procedures. The β-blockers and calcium antagonists-verapamil, which increase the diastolic filling time and improve ventricular diastolic function, are most commonly used. However, there are some limitations and side effects of these drugs. This article summarizes the current advances in drug therapy for HCM and reviews the latest literatures, clinical guidelines and the current clinical most commonly used treatment of HCM drugs and the latest research progress. While improving clinical symptoms of HCM, the drugs could reverse myocardial hypertrophy, reduce the pressure gradient and improve the prognosis need further in-depth study. Background Hypertrophic cardiaomyopathy (HCM) is characterized by asymmetric myocardial hypertrophy, mainly involving ventricular septum. Current treatment methods for HCM include drugs, interventional and surgical procedures. The β-blockers and calcium antagonists-verapamil, which increase the diastolic filling time and improve ventricular However, there are some limitations and side effects of these drugs. This article summarizes the current advances in drug therapy for HCM and reviews the latest literatures, clinical guidelines and the current clinical most commonly used treatment of HCM drugs and the latest research progress. While improving clinical symptoms of HCM, the drugs could reverse myocardial hypertrophy, reduce the pressure gradient and improve the prognosis need further in-depth study.